The hypothesis of this study are as follows:

• Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
• In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities.
• The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.

Inclusion criteria:

1. Patients with locally advanced or metastatic renal cell carcinoma
2. Whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor;
3. Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance Status) at treatment initiation time
4. With first-line treatment carried out between 2007 and June 2016.

Exclusion criteria:

1. Patient previously treated with only one cytokine (Interferon α2a, high-dose interleukin-2)
2. Refusal of processing of personal data

Patients with locally advanced or metastatic renal cell carcinoma, whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor